(Reuters) -Johnson & Johnson said on Thursday it will discontinue a late-stage study of its add-on treatment for major depressive disorder due to insufficient efficacy in the target patient population.
The company said it will explore future development opportunities for the drug, aticaprant, “in other areas of high unmet need”.
Full analyses from the study are underway and will be shared at a future medical meeting, J&J said.
(Reporting by Puyaan Singh in Bengaluru; Editing by Arun Koyyur and Krishna Chandra Eluri)
Comments